Holen Sie sich die Stockscreener-App
38.74
0.00%
0.00
Handel nachbörslich:
38.88
0.14
+0.36%
Schlusskurs vom Vortag:
$38.74
Offen:
$38.11
24-Stunden-Volumen:
5.36M
Relative Volume:
1.17
Marktkapitalisierung:
$78.35B
Einnahmen:
$40.10B
Nettoeinkommen (Verlust:
$3.26B
KGV:
24.47
EPS:
1.5831
Netto-Cashflow:
$4.57B
1W Leistung:
+0.44%
1M Leistung:
+3.06%
6M Leistung:
-5.23%
1J Leistung:
-9.63%
1-Tages-Spanne:
$37.88
$38.84
1-Wochen-Bereich:
$37.76
$39.31
52-Wochen-Spanne:
$31.71
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
Vergleichen Sie GSK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
38.74 | 78.35B | 40.10B | 3.26B | 4.57B | 1.5831 |
|
LLY
Lilly Eli Co
|
825.91 | 741.81B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
209.52 | 370.64B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
165.84 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
69.44 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
89.76 | 226.74B | 64.17B | 17.12B | 18.10B | 6.73 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - TradingView
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection - Yahoo Finance
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK - GlobeNewswire Inc.
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money - GlobeNewswire
How Do Things Look For GSK Plc ADR (NYSE: GSK) In The Short-Term? - Stocks Register
GSK Lead Plaintiff Deadline Approaching – Contact Robbins - GlobeNewswire
GSK Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action - TradingView
Why GSK (GSK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming DeadlinesGSK - PR Newswire
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - Zacks Investment Research
The Best Defensive Stocks to Buy Now - Morningstar
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Yahoo Finance
The Best Women-Led Companies to Own: 2025 Edition - Morningstar
GSK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Why weight-loss drugs are the top target of Medicare price negotiations - Equities News
GSK Securities Class Action: GSK PLC Investors Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the GSK Class Action Lawsuit - The Malaysian Reserve
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
Shareholder Rights Law Firm Robbins LLP Reminds GSK Investors with Large Losses to Seek Advice on Leading the GSK PLC Class Action - PR Newswire
A closer look at Gold Fields Ltd ADR’s (GFI) current quarter earnings projections - US Post News
Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Deadline Approaching: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Is GSK Plc ADR (GSK) worth investing in despite its undervalued state? - US Post News
Chewy Inc (CHWY) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Law Offices of Howard G. Smith Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
GSK PLC Stockholder Notice: Shareholder Rights Law Firm - GlobeNewswire
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):